Cambridge, UK-based Mission Therapeutics has appointed David Luther as chief financial officer.
Luther joins from Spotless Group, a private equity backed FMCG business, and brings over 25 years of financial and operational experience across healthcare and pharmaceutical industries.
He said: “I am very enthusiastic about joining the highly experienced Mission management team and look forward to working with them and the company’s investors to create and deliver value from the diverse therapeutic opportunities generated by the company’s discovery platform.”
Luther has also served as finance director for Aptuit, a global healthcare contract services organisation, and before this spent 15 years at GlaxoSmithKline holding numerous senior roles including director of corporate development.
Dr Anker Lundemose, CEO of Mission Therapeutics, said: “David’s financial acumen, extensive experience and exemplary track record in both large pharma and private equity-backed companies will be invaluable to Mission.
“This welcome appointment comes at a pivotal moment in our corporate development and complements the senior management team as our assets grow with the success of our discovery programmes.”